In the late '90s, biologic response modifiers changed expectations for patients with rheumatoid arthritis.

The most important advance has been the development of a group of drugs called biologic response modifiers or biologics.

Biologic response modifiers in primary immunodeficiency disorders.

The occurrence of fever is predictable for some drugs, such as biologic response modifiers, amphotericin B, and bleomycin.

Biologic response modifiers used in the treatment of malignant disease are associated with a wide variety of side effects and toxic effects.

People receiving cytotoxic chemotherapy, irradiation, and/or biologic response modifiers for treatment of malignancy are likely to experience pruritus.

Medications called biologic response modifiers have given new hope to people with rheumatoid arthritis (RA) and the doctors who treat them.

Also known as biologic response modifiers or biologic agents, biologics are geneticallyengineered therapies made from living organisms.

They can be administered alone or be linked (conjugated) to anticancer drugs, radioisotopes, or other biologic response modifiers.

Drug causes of fever include a variety of cytotoxic chemotherapy agents, biologic response modifiers, vancomycin, amphotericin, and multiple other medications.

Fever and related symptoms with biologic response modifier administration is type-, route-, dose-, and schedule-dependent.

Since they were first introduced in 1998, biologic response modifiers - or biologics - have made a huge difference in the lives of people with rheumatoid arthritis.

Referred to as biologic response modifiers, biologic agents, or simply biologics, these drugs target specific parts of an overactive immune system to reduce inflammation.

ENBREL is grouped within a class of medications called biologic response modifiers, or biologics.

Anti-rheumatic drugs and biologic response modifiers (DMARDs)

That requires a more powerful disease-modifying antirheumatic drug (DMARD) or biologic response modifier, or both.

Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18).